Lumens in a patient's body can change in size, shape, and/or patency, and such changes can present complications or affect associated bodily functions. For example, the walls of the vasculature, particularly arterial walls, may develop a pathological dilatation, commonly called an aneurysm. Aneurysms are observed as a ballooning-out of the wall of an artery. This is a result of the vessel wall being weakened by disease, injury, or a congenital abnormality. Aneurysms have thin, weak walls and have a tendency to rupture and are often caused or made worse by high blood pressure. Aneurysms can be found in different parts of the body; the most common being abdominal aortic aneurysms (AAA) and the brain or cerebral aneurysms. The mere presence of an aneurysm is not always life-threatening, but an aneurysm can have serious health consequences such as a stroke if one should rupture in the brain. Additionally, a ruptured aneurysm can also result in death.
The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples, and do not limit the subject technology. It is noted that any of the dependent clauses may be combined in any combination, and placed into a respective independent clause, e.g., clause 1, 16 and 23. The other clauses can be presented in a similar manner.
1. A system for treating a patient, the system comprising:
2. The system of clause 1, wherein the body comprises a braided structure.
3. The system of clause 1, wherein the body comprises a cut metal tube.
4. The system of clause 1, wherein the body comprises a self-expanding structure.
5. The system of clause 1, wherein an axial length of the expanding member in the collapsed configuration is about 200-500% longer than the axial length of the expanding member in an expanded configuration.
6. The system of clause 5, wherein a change in the axial length of the expanding member from the collapsed configuration to the expanded configuration is the same as a change in the axial length of the body from a body collapsed configuration to a body expanded configuration.
7. The system of clause 1, further comprising an adhesive disposed between the expanding member and the region for adhering a portion of the region to the expanding member.
8. The system of clause 7, wherein the adhesive comprises biodegradable material.
9. The system of clause 1, further comprising a corrugated tube disposed within the expanding member, the corrugated tube configured to axially shorten as the expanding member is inflated.
10. The system of clause 1, wherein the expanding member comprises, when expanded, an enlarged region having an enlarged diameter relative to other regions of the expanding member, the enlarged region being substantially axially aligned with the body region.
11. The system of clause 10, further comprising an adhesive disposed between the enlarged region of the expanding member and the body region.
12. The system of clause 1, wherein the expanding member comprises, when expanded, a reduced region having a reduced diameter relative to other regions of the expanding member, the reduced region being substantially axially aligned with the body region.
13. The system of clause 12, further comprising an adhesive disposed proximally or distally of the reduced region of the expanding member.
14. The system of clause 1, wherein the expanding member comprises, when expanded, two enlarged regions having an enlarged diameter relative to a reduced region therebetween, having a reduced diameter, the reduced region being substantially axially aligned with the body region.
15. The system of clause 14, further comprising an adhesive disposed between the enlarged regions and the body.
16. A delivery system for a vascular device, the delivery system comprising:
17. The system of clause 16, wherein an axial length of the expanding member in a collapsed configuration is about 200-500% longer than the axial length of the expanding member in a radially expanded configuration.
18. The system of clause 17, wherein a change in the axial length of the expanding member from the collapsed configuration to the radially expanded configuration is the same as a change in the axial length of the device from a device collapsed configuration to a device expanded configuration.
19. The system of clause 16, further comprising an adhesive disposed between the expanding member and the region for adhering a portion of the region to the expanding member.
20. The system of clause 16, wherein the expanding member comprises, when radially expanded, an enlarged region having an enlarged diameter relative to other regions of the expanding member, the enlarged region being substantially axially aligned with the region of the device.
21. The system of clause 16, wherein the expanding member comprises, when radially expanded, a reduced region having a reduced diameter relative to other regions of the expanding member, the reduced region being substantially axially aligned with the region of the device.
22. The system of clause 16, wherein the expanding member comprises, when radially expanded, two enlarged regions having an enlarged diameter relative to a reduced region therebetween, having a reduced diameter, the reduced region being substantially axially aligned with the region of the device.
It is understood that other configurations of the subject technology will become readily apparent to those skilled in the art from the following detailed description, wherein various configurations of the subject technology are shown and described by way of illustration. As will be realized, the subject technology is capable of other and different configurations and its several details are capable of modification in various other respects, all without departing from the scope of the subject technology. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not as restrictive.
A detailed description will be made with reference to the accompanying drawings:
The detailed description set forth below is intended as a description of various configurations of the subject technology and is not intended to represent the only configurations in which the subject technology may be practiced. The appended drawings are incorporated herein and constitute a part of the detailed description. The detailed description includes specific details for the purpose of providing a thorough understanding of the subject technology. However, it will be apparent to those skilled in the art that the subject technology may be practiced without these specific details. In some instances, well-known structures and components are shown in block diagram form in order to avoid obscuring the concepts of the subject technology.
Aneurysms may be located, for example, along vessel side walls. A neck of an aneurysm typically defines an opening of between about 2 to 25 mm, though other sizes and ranges are also possible. The neck connects an anatomical lumen to a fundus of the aneurysm. In some embodiments, “vessel” or “lumen” may refer to blood vessels (including arteries and veins) or other suitable body organs having a lumen, such as the gastrointestinal tract (e.g., esophagus, stomach, small intestine, colon, rectum), bile ducts, urinary bladder, ureter, urethra, trachea, bronchi, and the like. Blood flow within the anatomical lumen flows through the neck and into the fundus. In response to the constant blood flow into the fundus of the aneurysm, the wall of the aneurysm continues to distend and presents a significant risk of rupturing. When the blood within the aneurysm causes pressure against the wall of the aneurysm that exceeds the wall strength, the aneurysm ruptures.
Reduction of blood flow to or within the aneurysm results in a reduction in force against the wall of the aneurysm and a corresponding reduction in the risk of rupturing. A reduction of the force and volume of blood entering the aneurysm may be accomplished by an occluding device. Occluding devices may be dependent on a physician's skill during deployment, to ensure that a desired porosity is attained at the neck of the aneurysm. If the porosity too high at the neck, then the occluding device may fail in sufficiently reducing the blood flow into the fundus. The porosity of some occluding devices may be reduced by applying a longitudinally compressive force to a proximal portion of the occluding device towards the direction of a distal portion. Because the porosity of the occluding device may be modified by application of the compressive force, achieving the desired porosity consistently and reliably is heavily dependant on physician skill.
The methods and systems of the subject technology solve some or all of the foregoing problems by controlling the deployment of a vascular device such that the device occludes blood flow into the aneurysm consistently and reliably, to thereby prevent or reduce likelihood of aneurysm ruptures. The system includes an expandable vascular device and an expanding member positioned within a central lumen of the vascular device. The expanding member is configured to attain a predetermined porosity for a region of the device during deployment. Accordingly, controlling the deployment of the vascular device using the expanding member to attain the predetermined porosity for the region, reduces or stops the laminar flow into the aneurysm, thereby allowing the blood within the aneurysm to begin to stagnate. Stagnation of blood, as opposed to continuous flow through a fundus of the aneurysm, results in thrombosis in the aneurysm, which also helps protect the aneurysm from rupturing.
Referring to
Alternatively, the body 111 may be formed, for example, by laser cutting a pre-formed tube or sheet, by interconnecting a multitude of members 112 by laser welding, or by other suitable methods such as electrochemical etching, grinding, piercing, electroforming, or other means. In another example, the body 111 may comprise a tubular stent.
The body 111 has a porosity configured to reduce haemodynamic flow into, for example, an aneurysm. The porosity of the body 111, determined by the plurality of members 112, may be adjusted by axially shortening the body 111. The ends of the body 111 may be cut to length and therefore remain free for radial expansion and contraction. The body 111 may exhibit a high degree of flexibility due to the materials used, the porosity of the body 111, and the fact that the ends are not secured.
Referring to
The expanding member 120 is configured to geometrically deform in a similar manner as the vascular device 110, as the body 111 moves from the first, collapsed configuration to the second, expanded configuration. For example, during expansion of the expanding member 120 from the collapsed configuration to the expanded configuration, the expanding member 120 may be configured to shorten in axial length and increase in radial dimension, or diameter, by the same amounts as the body 111 does when the body 111 moves from the first, collapsed configuration to the second, expanded configuration. In other words, a change in the axial length and radial dimension of the expanding member 120 from the collapsed configuration to the expanded configuration is the same as a change in the axial length and radial dimension of the body 111 from the first, collapsed configuration to the second, expanded configuration.
The expanding member 120 may have an inner member 125 disposed within a central longitudinal axis of the expanding member 120 that is configured to axially shorten during expansion or inflation of the expanding member 120. The inner member 125 may be configured to axially shorten by the same amount as the expanding member 120 axially shortens during expansion or inflation. The inner member 125 may, for example, comprise a corrugated tube, telescoping tube, or other structure configured to axially shorten or collapse. A proximal and distal end of the expanding member 120 may be attached, coupled, or adhered to a proximal and distal portion of the inner member 125.
In some aspects, to reduce the tendency of the expanding member 120 to creep or stress relax, the material of the expanding member 120 may be cross-linked. Cross-links are bonds, bi-functional polymer chains or multi-functional polymer chains that link one polymer chain of the expanding member 120 material to another. Cross-links can be formed by chemical reactions that are initiated by heat, pressure, change in pH, radiation, or other means. For example, mixing of an unpolymerized or partially polymerized resin with specific chemicals called cross-linking reagents results in a chemical reaction that forms cross-links between the polymer chains of the expanding member 120 material. If further protection from creep or stress relaxation is desired, the expanding member 120 could be shipped in an axially shortened and radially expanded configuration, or in the expanded configuration. In this example, the expanding member 120 may be configured to be “at rest” when the expanding member 120 is at its largest diameter and its shortest length.
Referring to
Alternatively, the expanding member 120 may be manufactured by solution casting. Solution casting is a process in which the mold is rotated, causing a solution in the mold to conform to the interior surface of the mold due to centrifugal force. After the solution has cured into a film, the mold is disassembled, thereby releasing the expanding member 120.
Other known methods may also be used to manufacture the expanding member 120. In some examples the expanding member 120 is comprised of wound or braided filaments imbedded in the elastomeric polymer. In another example the expanding member 120 may be comprised of braided filaments which can be axially lengthened or shortened using a telescoping rod and tube, the rod being attached to distal ends of the braided filaments and the tube being attached to proximal ends of the braided filaments.
The expanding member 120 may have a proximal cuff 122A and a distal cuff 122B for attachment to a catheter 130. In another embodiment, the expanding member 120 may only have a proximal cuff 122A, as shown in
Alternatively, the expanding member 120 may be configured to controllably expand the vascular device 110 such that the vascular device 110 attains a predetermined porosity in more than one region, such as proximal and distal to the neck of the aneurysm where pressure may be higher.
Referring to
The adhesive 117 may comprise biodegradable materials, or materials that dissolve in the body or in the bloodstream. For example, the adhesive 117 may include sugar, carbowax, polyethylene oxide, poly vinyl alcohol, poly lactic acid (PLA), poly glycolic acid (PGA), poly lactic glycolic acid (PLGA), poly (c-caprolactone) copolymers, polydioxanone, poly(propylene fumarate) poly(trimethylene carbonate) copolymers, polyhydroxy alkanoates, polyphosphazenes, polyanhydrides, poly(ortho esters), poly(amino acids), or “pseudo”-poly(amino acids).
In some aspects, the expanding member 120 may be configured to allow perfusion of tissues downstream of the expanding member during expansion or inflation of the expanding member 120. Allowing perfusion of tissues downstream also aids in dissolution of the adhesive 117.
Referring to
Referring to
Alternatively, the adhesive 117 may be applied on the outer surface of the expanding member 120 while the expanding member 120 is deflated, partially collapsed, and/or in the collapsed configuration. In this example, the adhesive 117 may be applied continuously within the region 115A, as shown in
In another example, the adhesive 117 may be applied on the outer surface of the expanding member 120 while the expanding member 120 has a portion that is stretched along its length. The stretched portion may correspond to the region 115A of the vascular device 110.
In some aspects, the expanding member 120 and the vascular device 110 are positively engaged, coupled, attached, or adhered such that there is no shear strain in the adhesive 117 when the expanding member 120 and the vascular device 110 are in the expanded configuration. In other aspects, the expanding member 120 and the vascular device 110 are positively engaged, coupled, attached, or adhered such that there is enough shear strain in the adhesive 117, when the expanding member 120 and the vascular device 110 are fully expanded or in the expanded configuration, to fracture or sever the adhesive 117 and thereby release the vascular device 110 from the expanding member 120. In other aspects, the expanding member 120 and the vascular device 110 are positively engaged, coupled, attached, or adhered such that there is enough shear strain in the adhesive 117 when the expanding member 120 and the vascular device 110 are partially expanded to fracture or sever the adhesive 117 and thereby release the vascular device 110 from the expanding member 120 prior to full expansion of the expanding member 120. The shear strain of interest could be axial strain, hoop strain, or a combination of both.
Prior to deployment, the expanding member 120 may be moved to the collapsed configuration, with the vascular device 110 disposed thereon. When in the collapsed configuration, the region 115A of the body 111 will have a higher braid density and lower porosity than other portions of the body 111 due to the adhesive 117 bonding the region 115A to the expanding member 120. During subsequent expansion of the expanding member 120 and the vascular device 110, the overall porosity of the body 111 will decrease as the diameter of the vascular device 110 increases and the axial length of the vascular device 110 shortens. The porosity of the region 115A, however, also decreases and remains less porous than other portions of the body 111 during and after expansion.
Referring to
The enlarged region 123A of the expanding member 120 increases the diameter of the region 115B to a diameter that is larger than the diameter in other portions of the body 111. Enlarging the diameter of the region 115B causes the members 112 disposed on the other portions of the body 111 to be pulled toward the region 115B, thereby decreasing the porosity within the region 115B. Accordingly, the expanding member 120 causes a reduction in the porosity of the body 111 within the region 115B that is more than the reduction of the porosity of the body 111 outside the region 115B, to thereby attain the predetermined porosity for the region 115B.
In one aspect, the adhesive 117 may be used to positively engage, couple, attach, or adhere the region 115B of the vascular device 110 to the enlarged region 123A of the expanding member 120. The adhesive 117 assists in utilizing the axial shrinkage and radial expansion characteristics of the expanding member 120 to control the porosity of the vascular device 110 by positively engaging, coupling, attaching, or adhering the expanding member 120 to the vascular device 110. The adhesion between the region 115B of the vascular device 110 and the expanding member 120 ensures that upon deployment, the region 115B attains the predetermined porosity.
Once near the treatment site, the adhesive 117 would begin to dissolve. As the expanding member 120 is expanded, the remaining adhesive 117 will be fractured, thereby further facilitating dissolution of the adhesive 117. The expanding member 120 and the vascular device 110 would expand in the same manner, shortening in axial length while increasing in diameter. The enlarged region 123A of the expanding member 120 would expand to a diameter greater than other portions of the expanding member 120, thereby causing the density within the region 115B to increase and the porosity within the region 115B to decrease, more than the other portions of the body 111.
Referring to
In one aspect, the adhesive 117 may be used to adhere the proximal and/or distal portions of the body 111, with the region 115C unadhered, to the expanding member 120. In another example, the adhesive 117 may be disposed intermittently along the reduced region 123B, as shown in
Once near the treatment site, the adhesive 117 would begin to dissolve. As the expanding member 120 is expanded, the remaining adhesive 117 will be fractured, thereby further facilitating dissolution of the adhesive 117. The expanding member 120 and the vascular device 110 would expand in the same manner, shortening in axial length while increasing in diameter. The reduced region 123B of the expanding member 120, which houses the excess material of the region 115C, will begin to enlarge and deploy the excess material contained therein.
Referring to
In one aspect, the adhesive 117 may be used to adhere the proximal and/or distal portions of the body 111, with the region 115D unadhered, to the enlarged regions 124 of the expanding member 120. The adhesive 117 assists in maintaining the excess material of the region 115D within the reduced region 123C of the expanding member 120 so that upon deployment, the region 115D attains the predetermined porosity. Thus, upon expansion of the expanding member 120, the excess material of the region 115D stored at the reduced region 123C of the expanding member 120 will be deployed with comparatively reduced porosity.
Once near the treatment site, the adhesive 117 would begin to dissolve. As the expanding member 120 is expanded, the remaining adhesive 117 will be fractured, thereby further facilitating dissolution of the adhesive 117. The expanding member 120 and the vascular device 110 would expand in the same manner, shortening in axial length while increasing in diameter. The reduced region 123C of the expanding member 120, which houses the excess material of the region 115D, will begin to enlarge and deploy the excess material contained therein.
Radiopaque markers may be located adjacent the proximal or distal portions of the vascular device 110, and may be located at any position along the length of the vascular device 110 between a proximal and distal end of the vascular device 110, including the region 115A-D. The markers may be attached to the vascular device 110 by techniques such as adhesives, heat fusion, interference fit, fasteners, intermediate members, coatings, or by other techniques.
In some embodiments, the markers are comprised of ultrasonic markers, MRI-safe markers, or other markers. In some embodiments ultrasonic markers permit a physician to accurately determine the position of the vascular device 110 within a patient under ultrasonic visualization. Materials for an ultrasonic marker have an acoustical density sufficiently different from the vascular device 110 to provide suitable visualization via ultrasonic techniques. Exemplary materials comprise polymers, metals such as tantalum, platinum, gold, tungsten and alloys of such metals, hollow glass spheres or microspheres, and other materials.
In some embodiments, MRI-safe markers permit a physician to accurately determine the position of the vascular device 110 within a patient under magnetic resonance imaging. Exemplary materials for making MRI-safe marker have a magnetic signature sufficiently different from the vascular device 110 to provide suitable visualization via MRI techniques. Exemplary materials comprise polymers, metals such as tantalum, platinum, gold, tungsten and alloys of such metals, non-ferrous materials, and other materials.
A technique for treating an aneurysm will now be discussed with reference to
Referring to
Referring to
The fixed wire catheter includes a shaft having an inflation lumen only, to which is affixed a hub and the expanding member 120.
Referring to
The vascular device 110 and the expanding member 120 may be cooperatively movable within the outer sheath 140 in order to deliver the vascular device 110 to a treatment site, such as an aneurysm, within the vasculature of a patient.
The outer sheath 140 may be configured to be introduced and advanced through the vasculature of the patient. The outer sheath 140 may be made from various thermoplastics, e.g., PTFE, FEP, HDPE, PEEK, etc., which may optionally be lined on the inner surface of the outer sheath 140 or an adjacent surface with a hydrophilic material such as PVP or some other plastic coating. Additionally, either surface may be coated with various combinations of different materials, depending upon the desired results.
The shaft 131 includes the guide wire lumen 133 for allowing a guide wire 150 to extend therethrough. The shaft 131 may also include a reduced diameter at a distal region 137 to provide sufficient annular space in which the vascular device 110 is stowed. In this example, the expanding member 120 would be disposed on the reduced diameter region 137 of the shaft 131.
Radiopaque markers may be provided at various locations along the length of the system 100. For example, an enlarged distal tip 138 of the shaft 131 may be radiopaque. In another example, radiopaque markers may be provided on the reduced diameter distal region 137 of the shaft, beneath the distal and proximal end of the vascular device 110. In yet another example, a radiopaque marker 160 may be disposed on the shaft 131 adjacent to a longitudinal center of the vascular device 110 and/or the expanding member 120.
In one aspect, the vascular devices 110 may be configured with regions 115A-D having different axial lengths. A physician may select the appropriate vascular device 110 based on a size of the neck of the aneurysm and the axial length of the region 115A-D. For example, based on the axial length of the region 115A-D and a length of a neck of the aneurysm “Ln,” the vascular device 110 may be selected such that the axial length of the region 115A-D, when the vascular device 110 is in the second, expanded configuration, is longer than the length of the neck of the aneurysm.
In another aspect, the system 100 may be manufactured to ship with the expanding member 120 and the vascular device 110 in the expanded configuration. In this example, after the system 100 is selected such that the as-delivered axial length of the region 115A-D is longer than the length of the aneurysm, the physician may draw the vascular device 110 and the expanding member 120 assembly proximally into the outer sheath 140 to compress the vascular device and the expanding member 120 assembly. In an alternative embodiment, the system 100 may be manufactured to ship with the expanding member 120 and the vascular device 110 in the collapsed configuration, preloaded in the outer sheath 140.
Referring to
Referring to
If the vascular device 110 comprises a self-expanding stent, then portions of the vascular device that may be unadhered to the expanding member 120 may partially diametrically expand and partially axially shorten. In this example the region 115A-D will maintain a higher density and lower porosity than other portions of the body 111, during and after deployment, because of the adhesive 117 disposed between the region 115A-D and the expanding member 120. The adhesive 117 thereby allows the expandable member 120 to controllably expand the vascular device 110 and attain the predetermined porosity for the region 115A-D by positively engaging the vascular device 110. Alternatively, if the vascular device 110 does not comprise a self-expanding stent, then the vascular device 110 remains on the expanding member 120. As the outer sheath 140 is withdrawn, thereby exposing the vascular device 110 and the expanding member 120 assembly, the adhesive 117 begins to make contact with fluids, such as blood. The adhesive 117 begins to dissolve due to the contact with the fluid.
Referring to
Referring to
The expanding member 120 is then expanded to the fully expanded configuration, thereby fully deploying the vascular device 110. The expanding member 120 will diametrically expand and axially shrink, while maintaining the vascular device 110 to its outer surface due to the remaining adhesive 117 disposed between the vascular device 110 and the expanding member. The expanding member 120 controllably expands the vascular device 110 such that the vascular device 110 attains the predetermined porosity at the region 115A-D. During deployment, the expanding member 120 causes a reduction in the porosity of the body 111 within the region 115A-D that is more than the reduction of the porosity of the body 111 outside the region 115A-D, thereby attaining the predetermined porosity for the region 115A-D.
The adhesive 117 disposed between the expanding member 120 and the vascular device 110 may dissolve and/or fracture during or after expansion of the expanding member 120, thereby releasing the vascular device 110 from the expanding member 120.
The expanding member 120 thereby causes the region 115A-D to attain the pre-programmed porosity regardless of the endless variety of physician induced movements that can occur during the deployment of the vascular device 110. Stated another way, the porosity of the region 115A-D is relatively insensitive to physician applied motions during deployment of the vascular device 110.
Referring to
The region 115A-D of the vascular device 100 has a significantly lower porosity compared to other portions of the body 111. Due to the lower porosity of the region 115A-D, less blood flows into the aneurysm 210 such that substantial thrombosis may occur within the aneurysm 210.
In one arrangement, the vascular device 110 may be comprised of metal, polymer, ceramic, permanent enduring materials, and may comprise either of or both of non-bioabsorbable and bioabsorbable materials. Exemplary materials include, but are not limited to, NITINOL®, stainless steel, cobalt chromium alloys, Elgiloy, magnesium alloys, polylactic acid, poly glycolic acid, poly ester amide (PEA), poly ester urethane (PEU), amino acid based bioanalogous polymers, tungsten, tantalum, platinum, polymers, bio-polymers, ceramics, bio-ceramics, or metallic glasses. Part or all of the medical device may elute over time substances such as drugs, biologics, gene therapies, antithrombotics, coagulants, anti-inflammatory drugs, immunomodulator drugs, anti-proliferatives, migration inhibitors, extracellular matrix modulators, healing promoters, re-endothelialization promoters, or other materials. In some embodiments, the vascular device 110 may be formed from materials having shape memory properties. In some embodiments, the vascular device 110 may be finished by processes to remove slag. In some embodiments, the vascular device 110 may be subjected to a tempering treatment at temperatures customarily applied to the material so that the impressed structure is permanently established.
The vascular device 110 may have various lengths and diameters. For example, the vascular device 110 may have specific cross-sectional diameters, the diameters being measured when the vascular device 110 is fully free to expand, ranging from about 2 mm to about 6 mm. If the vascular device 110 has a diameter between 3 mm and 4 mm, it may be used in a size 18 microcatheters (i.e., microcatheters with an inner diameter of approximately 0.21 inch). If the vascular device 110 has a diameter between 5 mm and 6 mm, it may be used in a size 27 microcatheters (i.e., microcatheters with an inner diameter of approximately 0.027 inch). However, other suitable cross-sectional diameters may be used without deviating from the scope of the subject technology. In some embodiments, the vascular device 110 may have lengths, measured proximally to distally along the longitudinal axis of the vascular device 110, ranging from 15 mm to 40 mm, though other ranges and sizes are also possible.
Skilled artisans may implement the described functionality in varying ways for each particular application. Various components and blocks may be arranged differently (for example, arranged in a different order, or partitioned in a different way) all without departing from the scope of the subject technology. It is understood that the specific order or hierarchy of steps in the processes disclosed is an illustration of exemplary approaches. Based upon design preferences, it is understood that the specific order or hierarchy of steps in the processes may be rearranged. Some of the steps may be performed simultaneously. The accompanying method claims present elements of the various steps in a sample order, and are not meant to be limited to the specific order or hierarchy presented.
The previous description is provided to enable any person skilled in the art to practice the various aspects described herein. The previous description provides various examples of the subject technology, and the subject technology is not limited to these examples. Various modifications to these aspects will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other aspects. Thus, the claims are not intended to be limited to the aspects shown herein, but is to be accorded the full scope consistent with the language claims, wherein reference to an element in the singular is not intended to mean “one and only one” unless specifically so stated, but rather “one or more.” Unless specifically stated otherwise, the term “some” refers to one or more. Pronouns in the masculine (for example, his) include the feminine and neuter gender (for example, her and its) and vice versa. Headings and subheadings, if any, are used for convenience only and do not limit the invention.
A phrase such as an “aspect” does not imply that such aspect is essential to the subject technology or that such aspect applies to all configurations of the subject technology. A disclosure relating to an aspect may apply to all configurations, or one or more configurations. An aspect may provide one or more examples. A phrase such as an aspect may refer to one or more aspects and vice versa. A phrase such as an “aspect” does not imply that such aspect is essential to the subject technology or that such aspect applies to all configurations of the subject technology. A disclosure relating to an aspect may apply to all aspects, or one or more aspects. An aspect may provide one or more examples. A phrase such as an “aspect” may refer to one or more aspects and vice versa. A phrase such as a “configuration” does not imply that such configuration is essential to the subject technology or that such configuration applies to all configurations of the subject technology. A disclosure relating to a configuration may apply to all configurations, or one or more configurations. A configuration may provide one or more examples. A phrase such as a “configuration” may refer to one or more configurations and vice versa.
The word “exemplary” is used herein to mean “serving as an example or illustration.” Any aspect or design described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other aspects or designs.
All structural and functional equivalents to the elements of the various aspects described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and are intended to be encompassed by the claims. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the claims. No claim element is to be construed under the provisions of 35 U.S.C. §112, sixth paragraph, unless the element is expressly recited using the phrase “means for” or, in the case of a method claim, the element is recited using the phrase “step for.” Furthermore, to the extent that the term “include,” “have,” or the like is used in the description or the claims, such term is intended to be inclusive in a manner similar to the term “comprise” as “comprise” is interpreted when employed as a transitional word in a claim.
This application is a continuation of U.S. patent application Ser. No. 13/826,971, filed Mar. 14, 2013, which claims priority benefit of U.S. Provisional Application Ser. No. 61/720,154, filed Oct. 30, 2012, each of which is hereby incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2919467 | Mercer | Jan 1960 | A |
4321711 | Mano | Mar 1982 | A |
4503569 | Dotter | Mar 1985 | A |
4512338 | Balko et al. | Apr 1985 | A |
4538622 | Samson et al. | Sep 1985 | A |
4572186 | Gould et al. | Feb 1986 | A |
4580568 | Gianturco | Apr 1986 | A |
4655771 | Wallsten | Apr 1987 | A |
4681110 | Wiktor | Jul 1987 | A |
4733665 | Palmaz | Mar 1988 | A |
4743251 | Barra | May 1988 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4776337 | Palmaz | Oct 1988 | A |
4856516 | Hillstead | Aug 1989 | A |
4954126 | Wallsten | Sep 1990 | A |
5011488 | Ginsburg | Apr 1991 | A |
5035706 | Giantureo et al. | Jul 1991 | A |
5041126 | Gianturco | Aug 1991 | A |
5061275 | Wallsten et al. | Oct 1991 | A |
5108416 | Ryan et al. | Apr 1992 | A |
5160341 | Brenneman et al. | Nov 1992 | A |
5180368 | Garrison | Jan 1993 | A |
5192297 | Hull | Mar 1993 | A |
5197978 | Hess | Mar 1993 | A |
5201757 | Heyn et al. | Apr 1993 | A |
5209731 | Sterman et al. | May 1993 | A |
5242399 | Lau et al. | Sep 1993 | A |
5246420 | Kraus et al. | Sep 1993 | A |
5246445 | Yachia et al. | Sep 1993 | A |
5330500 | Song | Jul 1994 | A |
5344426 | Lau et al. | Sep 1994 | A |
5360443 | Barone et al. | Nov 1994 | A |
5382259 | Phelps et al. | Jan 1995 | A |
5401257 | Chevalier, Jr. et al. | Mar 1995 | A |
5405377 | Cragg | Apr 1995 | A |
5405380 | Gianotti et al. | Apr 1995 | A |
5415637 | Khosravi | May 1995 | A |
5421826 | Crocker et al. | Jun 1995 | A |
5423849 | Engelson et al. | Jun 1995 | A |
5449372 | Schmaltz et al. | Sep 1995 | A |
5458615 | Klemm et al. | Oct 1995 | A |
5476505 | Limon | Dec 1995 | A |
5480423 | Ravenscroft et al. | Jan 1996 | A |
5484444 | Braunschweiler | Jan 1996 | A |
5489295 | Piplani et al. | Feb 1996 | A |
5507767 | Maeda et al. | Apr 1996 | A |
5507768 | Lau et al. | Apr 1996 | A |
5522822 | Phelps et al. | Jun 1996 | A |
5534007 | St. Germain et al. | Jul 1996 | A |
5545208 | Wolff et al. | Aug 1996 | A |
5546880 | Ronyak et al. | Aug 1996 | A |
5549662 | Fordenbacher | Aug 1996 | A |
5562641 | Flomenblit et al. | Oct 1996 | A |
5562728 | Lazarus et al. | Oct 1996 | A |
5591225 | Okuda | Jan 1997 | A |
5599291 | Balbierz et al. | Feb 1997 | A |
5601593 | Freitag | Feb 1997 | A |
5607466 | Imbert et al. | Mar 1997 | A |
5609625 | Piplani et al. | Mar 1997 | A |
5626602 | Gianotti et al. | May 1997 | A |
5628783 | Quiachon et al. | May 1997 | A |
5628788 | Pinchuk | May 1997 | A |
5632771 | Boatman et al. | May 1997 | A |
5632772 | Alcime et al. | May 1997 | A |
5636641 | Fariabi | Jun 1997 | A |
5637113 | Tartaglia et al. | Jun 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5645559 | Hachtman et al. | Jul 1997 | A |
D381932 | Walshe et al. | Aug 1997 | S |
5667522 | Flomenblit et al. | Sep 1997 | A |
5674276 | Andersen et al. | Oct 1997 | A |
5683451 | Lenker et al. | Nov 1997 | A |
5690120 | Jacobsen | Nov 1997 | A |
5690644 | Yurek et al. | Nov 1997 | A |
5695499 | Helgerson et al. | Dec 1997 | A |
5700269 | Pinchuk et al. | Dec 1997 | A |
5702418 | Ravenscroft | Dec 1997 | A |
5709702 | Cogita | Jan 1998 | A |
5709703 | Lukic et al. | Jan 1998 | A |
5718159 | Thompson | Feb 1998 | A |
5725570 | Heath | Mar 1998 | A |
5733327 | Igaki et al. | Mar 1998 | A |
5735859 | Fischell et al. | Apr 1998 | A |
5741325 | Chaikof et al. | Apr 1998 | A |
5741333 | Frid | Apr 1998 | A |
5746765 | Kleshinski et al. | May 1998 | A |
5749883 | Halpern | May 1998 | A |
5749920 | Quiachon et al. | May 1998 | A |
5769884 | Solovay | Jun 1998 | A |
5769885 | Quiachon et al. | Jun 1998 | A |
5776099 | Tremulis | Jul 1998 | A |
5776142 | Gunderson | Jul 1998 | A |
5782909 | Quiachon et al. | Jul 1998 | A |
5797952 | Klein | Aug 1998 | A |
5800518 | Piplani et al. | Sep 1998 | A |
5810837 | Hofmann et al. | Sep 1998 | A |
5817102 | Johnson et al. | Oct 1998 | A |
5817105 | Van Der Brug | Oct 1998 | A |
5824039 | Piplani et al. | Oct 1998 | A |
5824041 | Lenker et al. | Oct 1998 | A |
5824042 | Lombardi et al. | Oct 1998 | A |
5824044 | Quiachon et al. | Oct 1998 | A |
5824058 | Ravenscroft et al. | Oct 1998 | A |
5830229 | Konya et al. | Nov 1998 | A |
5833632 | Jacobsen et al. | Nov 1998 | A |
5836868 | Ressemann et al. | Nov 1998 | A |
5843168 | Dang | Dec 1998 | A |
5868754 | Levine et al. | Feb 1999 | A |
5876419 | Carpenter et al. | Mar 1999 | A |
5876445 | Andersen | Mar 1999 | A |
5888201 | Stinson et al. | Mar 1999 | A |
5902266 | Leone et al. | May 1999 | A |
5902317 | Kleshinski et al. | May 1999 | A |
5906640 | Penn et al. | May 1999 | A |
5911717 | Jacobsen et al. | Jun 1999 | A |
5916194 | Jacobsen et al. | Jun 1999 | A |
5919204 | Lukic et al. | Jul 1999 | A |
5928260 | Chin et al. | Jul 1999 | A |
5944728 | Bates | Aug 1999 | A |
5951599 | McCrory | Sep 1999 | A |
5957973 | Quiachon et al. | Sep 1999 | A |
5957974 | Thompson et al. | Sep 1999 | A |
5964797 | Ho | Oct 1999 | A |
5980530 | Willard | Nov 1999 | A |
5980533 | Holman | Nov 1999 | A |
5984957 | Laptewicz, Jr. et al. | Nov 1999 | A |
6012277 | Prins et al. | Jan 2000 | A |
6014919 | Jacobsen et al. | Jan 2000 | A |
6015432 | Rakos et al. | Jan 2000 | A |
6017319 | Jacobsen et al. | Jan 2000 | A |
6019778 | Wilson et al. | Feb 2000 | A |
6019786 | Thompson | Feb 2000 | A |
6022369 | Jacobsen et al. | Feb 2000 | A |
6024754 | Engelson | Feb 2000 | A |
6024763 | Lenker et al. | Feb 2000 | A |
6027516 | Kolobow et al. | Feb 2000 | A |
6033436 | Steinke et al. | Mar 2000 | A |
6039721 | Johnson | Mar 2000 | A |
6039758 | Quiachon et al. | Mar 2000 | A |
6042589 | Marianne | Mar 2000 | A |
6051021 | Frid | Apr 2000 | A |
6056993 | Leidner et al. | May 2000 | A |
6063111 | Hieshima et al. | May 2000 | A |
6074407 | Levine et al. | Jun 2000 | A |
6077295 | Limon et al. | Jun 2000 | A |
6080191 | Summers | Jun 2000 | A |
6083257 | Taylor et al. | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096052 | Callister et al. | Aug 2000 | A |
6102942 | Ahari | Aug 2000 | A |
6123712 | Di Caprio et al. | Sep 2000 | A |
6126685 | Lenker et al. | Oct 2000 | A |
6132459 | Piplani et al. | Oct 2000 | A |
6139543 | Esch et al. | Oct 2000 | A |
6146415 | Fitz | Nov 2000 | A |
6149680 | Shelso et al. | Nov 2000 | A |
6159228 | Frid et al. | Dec 2000 | A |
6161399 | Jayaraman | Dec 2000 | A |
6165194 | Denardo | Dec 2000 | A |
6165210 | Lau et al. | Dec 2000 | A |
6165213 | Goicoechea et al. | Dec 2000 | A |
6168592 | Kupiecki et al. | Jan 2001 | B1 |
6174330 | Stinson | Jan 2001 | B1 |
6183410 | Jacobsen et al. | Feb 2001 | B1 |
6183508 | Stinson et al. | Feb 2001 | B1 |
6187013 | Stoltze et al. | Feb 2001 | B1 |
6193708 | Ken et al. | Feb 2001 | B1 |
6197046 | Piplani et al. | Mar 2001 | B1 |
6203569 | Wijay | Mar 2001 | B1 |
6206868 | Parodi | Mar 2001 | B1 |
6210400 | Hebert et al. | Apr 2001 | B1 |
6210434 | Quiachon et al. | Apr 2001 | B1 |
6210435 | Piplani et al. | Apr 2001 | B1 |
6214038 | Piplani et al. | Apr 2001 | B1 |
6214042 | Jacobsen et al. | Apr 2001 | B1 |
6221102 | Baker et al. | Apr 2001 | B1 |
6224609 | Ressemann et al. | May 2001 | B1 |
6224829 | Piplani et al. | May 2001 | B1 |
6231598 | Berry et al. | May 2001 | B1 |
6235050 | Quiachon et al. | May 2001 | B1 |
6241759 | Piplani et al. | Jun 2001 | B1 |
6245087 | Addis | Jun 2001 | B1 |
6245103 | Stinson | Jun 2001 | B1 |
6251132 | Ravenscroft et al. | Jun 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6260458 | Jacobsen et al. | Jul 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6261316 | Shaolian et al. | Jul 2001 | B1 |
6264671 | Stack | Jul 2001 | B1 |
6264689 | Colgan et al. | Jul 2001 | B1 |
6270523 | Herweck et al. | Aug 2001 | B1 |
6280465 | Cryer | Aug 2001 | B1 |
6283991 | Cox et al. | Sep 2001 | B1 |
6287331 | Heath | Sep 2001 | B1 |
6287333 | Appling et al. | Sep 2001 | B1 |
6290721 | Heath | Sep 2001 | B1 |
6299636 | Schmitt et al. | Oct 2001 | B1 |
6302810 | Yokota | Oct 2001 | B2 |
6302893 | Limon et al. | Oct 2001 | B1 |
6309353 | Cheng et al. | Oct 2001 | B1 |
6322576 | Wallace et al. | Nov 2001 | B1 |
6322586 | Monroe et al. | Nov 2001 | B1 |
6322587 | Quiachon et al. | Nov 2001 | B1 |
6325826 | Vardi et al. | Dec 2001 | B1 |
6334871 | Dor et al. | Jan 2002 | B1 |
6336938 | Kavteladze et al. | Jan 2002 | B1 |
6340367 | Stinson et al. | Jan 2002 | B1 |
6340368 | Verbeck | Jan 2002 | B1 |
6342068 | Thompson | Jan 2002 | B1 |
6344041 | Kupiecki et al. | Feb 2002 | B1 |
6348063 | Yassour et al. | Feb 2002 | B1 |
6350199 | Williams et al. | Feb 2002 | B1 |
6350278 | Lenker et al. | Feb 2002 | B1 |
6355051 | Sisskind et al. | Mar 2002 | B1 |
6355061 | Quaichon | Mar 2002 | B1 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6368339 | Amplatz | Apr 2002 | B1 |
6368344 | Fitz | Apr 2002 | B1 |
6368557 | Piplani et al. | Apr 2002 | B1 |
6375670 | Greenhalgh | Apr 2002 | B1 |
6375676 | Cox | Apr 2002 | B1 |
6379618 | Piplani et al. | Apr 2002 | B1 |
6380457 | Yurek et al. | Apr 2002 | B1 |
6389946 | Frid | May 2002 | B1 |
6395017 | Dwyer et al. | May 2002 | B1 |
6395021 | Hart et al. | May 2002 | B1 |
6395022 | Piplani et al. | May 2002 | B1 |
6398802 | Yee | Jun 2002 | B1 |
6409683 | Fonseca et al. | Jun 2002 | B1 |
6413235 | Parodi | Jul 2002 | B1 |
6416519 | VanDusseldorp | Jul 2002 | B1 |
6416536 | Yee | Jul 2002 | B1 |
6419693 | Fariabi | Jul 2002 | B1 |
6428489 | Jacobsen et al. | Aug 2002 | B1 |
6440088 | Jacobsen et al. | Aug 2002 | B1 |
6443971 | Boylan et al. | Sep 2002 | B1 |
6443979 | Stalker | Sep 2002 | B1 |
6454999 | Farhangnia et al. | Sep 2002 | B1 |
6468301 | Amplatz et al. | Oct 2002 | B1 |
6477768 | Wildner | Nov 2002 | B1 |
6478778 | Jacobsen et al. | Nov 2002 | B1 |
6482221 | Hebert et al. | Nov 2002 | B1 |
6488705 | Schmitt et al. | Dec 2002 | B2 |
6491648 | Cornish et al. | Dec 2002 | B1 |
6494895 | Addis | Dec 2002 | B2 |
6497711 | Plaia et al. | Dec 2002 | B1 |
6503450 | Afzal | Jan 2003 | B1 |
6514261 | Randall et al. | Feb 2003 | B1 |
6514285 | Pinchasik | Feb 2003 | B1 |
6524299 | Tran et al. | Feb 2003 | B1 |
6527763 | Esch et al. | Mar 2003 | B2 |
6533811 | Ryan et al. | Mar 2003 | B1 |
6540778 | Quiachon et al. | Apr 2003 | B1 |
6547779 | Levine | Apr 2003 | B2 |
6551352 | Clerc et al. | Apr 2003 | B2 |
6572646 | Boylan et al. | Jun 2003 | B1 |
6576006 | Limon et al. | Jun 2003 | B2 |
6582460 | Cryer | Jun 2003 | B1 |
6582461 | Burmeister et al. | Jun 2003 | B1 |
6589273 | McDermott | Jul 2003 | B1 |
6592616 | Stack et al. | Jul 2003 | B1 |
6595989 | Scheer | Jul 2003 | B1 |
6602271 | Adams et al. | Aug 2003 | B2 |
6602280 | Chobotov | Aug 2003 | B2 |
6605110 | Harrison | Aug 2003 | B2 |
6613075 | Healy et al. | Sep 2003 | B1 |
6613078 | Barone | Sep 2003 | B1 |
6622604 | Chouinard et al. | Sep 2003 | B1 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6638243 | Kupiecki | Oct 2003 | B2 |
6645240 | Yee | Nov 2003 | B2 |
6646218 | Campbell et al. | Nov 2003 | B1 |
6652508 | Griffin | Nov 2003 | B2 |
6652574 | Jayaraman | Nov 2003 | B1 |
6656212 | Ravenscroft et al. | Dec 2003 | B2 |
6656218 | Denardo et al. | Dec 2003 | B1 |
6660024 | Flaherty | Dec 2003 | B1 |
6660032 | Klumb et al. | Dec 2003 | B2 |
6663666 | Quiachon et al. | Dec 2003 | B1 |
6666881 | Richter et al. | Dec 2003 | B1 |
6669719 | Wallace | Dec 2003 | B2 |
6673089 | Yassour et al. | Jan 2004 | B1 |
6673100 | Diaz et al. | Jan 2004 | B2 |
6679893 | Tran | Jan 2004 | B1 |
6682557 | Quiachon et al. | Jan 2004 | B1 |
6685735 | Ahari | Feb 2004 | B1 |
6689120 | Gerdts | Feb 2004 | B1 |
6689162 | Thompson | Feb 2004 | B1 |
6699274 | Stinson | Mar 2004 | B2 |
6702843 | Brown et al. | Mar 2004 | B1 |
6709454 | Cox et al. | Mar 2004 | B1 |
6712834 | Yassour et al. | Mar 2004 | B2 |
6726700 | Levine | Apr 2004 | B1 |
6733519 | Lashinski et al. | May 2004 | B2 |
6740105 | Yodfat et al. | May 2004 | B2 |
6740112 | Yodfat et al. | May 2004 | B2 |
6743219 | Dwyer et al. | Jun 2004 | B1 |
6755855 | Yurek et al. | Jun 2004 | B2 |
6758885 | Leffel et al. | Jul 2004 | B2 |
6767361 | Quiachon et al. | Jul 2004 | B2 |
6773446 | Dwyer et al. | Aug 2004 | B1 |
6793667 | Hebert et al. | Sep 2004 | B2 |
6814746 | Thompson et al. | Nov 2004 | B2 |
6814748 | Baker et al. | Nov 2004 | B1 |
6818006 | Douk et al. | Nov 2004 | B2 |
6833003 | Jones et al. | Dec 2004 | B2 |
6849084 | Rabkin et al. | Feb 2005 | B2 |
6858034 | Hijlkema et al. | Feb 2005 | B1 |
6860893 | Wallace et al. | Mar 2005 | B2 |
6860898 | Stack et al. | Mar 2005 | B2 |
6860899 | Rivelli, Jr. | Mar 2005 | B1 |
6860900 | Clerc et al. | Mar 2005 | B2 |
6860901 | Baker et al. | Mar 2005 | B1 |
6866677 | Douk et al. | Mar 2005 | B2 |
6866679 | Kusleika | Mar 2005 | B2 |
6866680 | Yassour et al. | Mar 2005 | B2 |
6881221 | Golds | Apr 2005 | B2 |
6887267 | Dworschak et al. | May 2005 | B2 |
6890337 | Feeser et al. | May 2005 | B2 |
6893451 | Cano et al. | May 2005 | B2 |
6918921 | Brady et al. | Jul 2005 | B2 |
6932837 | Amplatz et al. | Aug 2005 | B2 |
6936055 | Ken et al. | Aug 2005 | B1 |
6955685 | Escamilla et al. | Oct 2005 | B2 |
6960227 | Jones et al. | Nov 2005 | B2 |
6964670 | Shah et al. | Nov 2005 | B1 |
6964672 | Brady et al. | Nov 2005 | B2 |
6969396 | Krolik et al. | Nov 2005 | B2 |
6976991 | Hebert et al. | Dec 2005 | B2 |
6989024 | Hebert et al. | Jan 2006 | B2 |
6994721 | Israel | Feb 2006 | B2 |
7001422 | Escamilla et al. | Feb 2006 | B2 |
7004962 | Stinson | Feb 2006 | B2 |
7004964 | Thompson et al. | Feb 2006 | B2 |
7011675 | Hemerick et al. | Mar 2006 | B2 |
7037330 | Rivelli, Jr. et al. | May 2006 | B1 |
7041129 | Rourke et al. | May 2006 | B2 |
7066951 | Chobotov | Jun 2006 | B2 |
7069835 | Nishri et al. | Jul 2006 | B2 |
7074236 | Rabkin et al. | Jul 2006 | B2 |
7093527 | Rapaport et al. | Aug 2006 | B2 |
7101392 | Heath | Sep 2006 | B2 |
7107105 | Bjorklund et al. | Sep 2006 | B2 |
7118539 | Vrba et al. | Oct 2006 | B2 |
7118594 | Quiachon et al. | Oct 2006 | B2 |
7122050 | Randall et al. | Oct 2006 | B2 |
7137990 | Hebert et al. | Nov 2006 | B2 |
7166125 | Baker et al. | Jan 2007 | B1 |
7169170 | Widenhouse | Jan 2007 | B2 |
7169172 | Levine et al. | Jan 2007 | B2 |
7172617 | Colgan et al. | Feb 2007 | B2 |
7192434 | Anderson et al. | Mar 2007 | B2 |
7195639 | Quiachon et al. | Mar 2007 | B2 |
7195648 | Jones et al. | Mar 2007 | B2 |
7201768 | Diaz et al. | Apr 2007 | B2 |
7201769 | Jones et al. | Apr 2007 | B2 |
7211109 | Thompson | May 2007 | B2 |
7213495 | McCullagh et al. | May 2007 | B2 |
7220271 | Clubb et al. | May 2007 | B2 |
7235096 | Van Tassel et al. | Jun 2007 | B1 |
7264632 | Wright et al. | Sep 2007 | B2 |
7275471 | Nishri et al. | Oct 2007 | B2 |
7279005 | Stinson | Oct 2007 | B2 |
7279208 | Goffena et al. | Oct 2007 | B1 |
7294137 | Riveili, Jr. et al. | Nov 2007 | B2 |
7294146 | Chew et al. | Nov 2007 | B2 |
7300456 | Andreas et al. | Nov 2007 | B2 |
7300460 | Levine et al. | Nov 2007 | B2 |
7306624 | Yodfat et al. | Dec 2007 | B2 |
7309351 | Escamilla et al. | Dec 2007 | B2 |
7311031 | McCullagh et al. | Dec 2007 | B2 |
7320702 | Hammersmark et al. | Jan 2008 | B2 |
7323001 | Clubb et al. | Jan 2008 | B2 |
7331973 | Gesswein et al. | Feb 2008 | B2 |
7331976 | McGuckin, Jr. et al. | Feb 2008 | B2 |
7331985 | Thompson et al. | Feb 2008 | B2 |
7338518 | Chobotov | Mar 2008 | B2 |
7438712 | Chouinard | Oct 2008 | B2 |
7462192 | Norton et al. | Dec 2008 | B2 |
7468070 | Henry et al. | Dec 2008 | B2 |
7470282 | Shelso | Dec 2008 | B2 |
7473271 | Gunderson | Jan 2009 | B2 |
7491224 | Cox et al. | Feb 2009 | B2 |
7520893 | Rivelli, Jr. | Apr 2009 | B2 |
RE40816 | Taylor et al. | Jun 2009 | E |
7572288 | Cox | Aug 2009 | B2 |
7572290 | Yodfat et al. | Aug 2009 | B2 |
7588597 | Frid | Sep 2009 | B2 |
7695507 | Rivelli, Jr. et al. | Apr 2010 | B2 |
7763011 | Ortiz et al. | Jul 2010 | B2 |
7771463 | Ton et al. | Aug 2010 | B2 |
7854760 | Molaei et al. | Dec 2010 | B2 |
7901447 | Molaei et al. | Mar 2011 | B2 |
7942925 | Yodfat et al. | May 2011 | B2 |
8007529 | Yan | Aug 2011 | B2 |
8092486 | Berrada et al. | Jan 2012 | B2 |
8092508 | Leynov et al. | Jan 2012 | B2 |
8192484 | Frid | Jun 2012 | B2 |
8382825 | Garcia et al. | Feb 2013 | B2 |
8394119 | Zaver et al. | Mar 2013 | B2 |
8398701 | Berez et al. | Mar 2013 | B2 |
8617234 | Garcia et al. | Dec 2013 | B2 |
8623067 | Berez et al. | Jan 2014 | B2 |
8628564 | Berez et al. | Jan 2014 | B2 |
8764817 | Sheldon | Jul 2014 | B2 |
8801772 | Shobayashi et al. | Aug 2014 | B2 |
8979918 | Murayama | Mar 2015 | B2 |
9050205 | Berez et al. | Jun 2015 | B2 |
9114001 | Kusleika et al. | Aug 2015 | B2 |
9125659 | Berez et al. | Sep 2015 | B2 |
9301831 | Kusleika | Apr 2016 | B2 |
9452070 | Kusleika | Sep 2016 | B2 |
20010027338 | Greenberg | Oct 2001 | A1 |
20010044651 | Steinke et al. | Nov 2001 | A1 |
20010049547 | Moore | Dec 2001 | A1 |
20010056299 | Thompson | Dec 2001 | A1 |
20020004667 | Adams et al. | Jan 2002 | A1 |
20020007194 | Plowiecki | Jan 2002 | A1 |
20020029061 | Amplatz et al. | Mar 2002 | A1 |
20020035396 | Heath | Mar 2002 | A1 |
20020062091 | Jacobsen et al. | May 2002 | A1 |
20020078808 | Jacobsen et al. | Jun 2002 | A1 |
20020082558 | Samson et al. | Jun 2002 | A1 |
20020087119 | Parodi | Jul 2002 | A1 |
20020111633 | Stoltze et al. | Aug 2002 | A1 |
20020111648 | Kusleika et al. | Aug 2002 | A1 |
20020120323 | Thompson et al. | Aug 2002 | A1 |
20020138133 | Lenz et al. | Sep 2002 | A1 |
20020143361 | Douk et al. | Oct 2002 | A1 |
20020143384 | Ozasa | Oct 2002 | A1 |
20020169473 | Sepetka et al. | Nov 2002 | A1 |
20020169474 | Kusleika et al. | Nov 2002 | A1 |
20020173839 | Leopold et al. | Nov 2002 | A1 |
20020188314 | Anderson et al. | Dec 2002 | A1 |
20020193864 | Khosravi et al. | Dec 2002 | A1 |
20030009215 | Mayer | Jan 2003 | A1 |
20030023299 | Amplatz et al. | Jan 2003 | A1 |
20030069522 | Jacobsen et al. | Apr 2003 | A1 |
20030100945 | Yodfat et al. | May 2003 | A1 |
20030130684 | Brady et al. | Jul 2003 | A1 |
20030135258 | Andreas et al. | Jul 2003 | A1 |
20030163155 | Haverkost et al. | Aug 2003 | A1 |
20030163156 | Hebert et al. | Aug 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030187495 | Cully et al. | Oct 2003 | A1 |
20030212429 | Keegan | Nov 2003 | A1 |
20030212430 | Bose et al. | Nov 2003 | A1 |
20040024416 | Yodfat et al. | Feb 2004 | A1 |
20040030265 | Murayama et al. | Feb 2004 | A1 |
20040044395 | Nelson | Mar 2004 | A1 |
20040073300 | Chouinard et al. | Apr 2004 | A1 |
20040088037 | Nachreiner et al. | May 2004 | A1 |
20040093010 | Gesswein et al. | May 2004 | A1 |
20040098099 | McCullagh et al. | May 2004 | A1 |
20040133223 | Weber | Jul 2004 | A1 |
20040153117 | Clubb et al. | Aug 2004 | A1 |
20040162606 | Thompson | Aug 2004 | A1 |
20040172055 | Huter et al. | Sep 2004 | A1 |
20040186368 | Ramzpoor et al. | Sep 2004 | A1 |
20040193178 | Nikolchev | Sep 2004 | A1 |
20040193179 | Nikolchev | Sep 2004 | A1 |
20040193208 | Talpade et al. | Sep 2004 | A1 |
20040199243 | Yodfat | Oct 2004 | A1 |
20040210235 | Deshmukh et al. | Oct 2004 | A1 |
20040215332 | Frid | Oct 2004 | A1 |
20040220585 | Nikolchev | Nov 2004 | A1 |
20040220608 | D'Aquanni et al. | Nov 2004 | A1 |
20040220663 | Rivelli | Nov 2004 | A1 |
20040254628 | Nazzaro et al. | Dec 2004 | A1 |
20040260331 | D'Aquanni et al. | Dec 2004 | A1 |
20050004595 | Boyle et al. | Jan 2005 | A1 |
20050021075 | Bonnette et al. | Jan 2005 | A1 |
20050033407 | Weber et al. | Feb 2005 | A1 |
20050038447 | Huffmaster | Feb 2005 | A1 |
20050051243 | Forbes Jones et al. | Mar 2005 | A1 |
20050055047 | Greenhalgh | Mar 2005 | A1 |
20050059889 | Mayer | Mar 2005 | A1 |
20050060017 | Fischell et al. | Mar 2005 | A1 |
20050090888 | Hines et al. | Apr 2005 | A1 |
20050101989 | Cully et al. | May 2005 | A1 |
20050137680 | Ortiz et al. | Jun 2005 | A1 |
20050149111 | Kanazawa et al. | Jul 2005 | A1 |
20050165441 | McGuckin et al. | Jul 2005 | A1 |
20050177186 | Cully et al. | Aug 2005 | A1 |
20050192620 | Cully et al. | Sep 2005 | A1 |
20050197689 | Molaei | Sep 2005 | A1 |
20050209672 | George et al. | Sep 2005 | A1 |
20050209678 | Henkes et al. | Sep 2005 | A1 |
20050246010 | Alexander et al. | Nov 2005 | A1 |
20050267568 | Berez et al. | Dec 2005 | A1 |
20050283220 | Gobran et al. | Dec 2005 | A1 |
20050288764 | Snow | Dec 2005 | A1 |
20050288766 | Plain et al. | Dec 2005 | A1 |
20060020324 | Schmid et al. | Jan 2006 | A1 |
20060036309 | Hebert et al. | Feb 2006 | A1 |
20060089703 | Escamilla et al. | Apr 2006 | A1 |
20060095213 | Escamilla et al. | May 2006 | A1 |
20060111771 | Ton et al. | May 2006 | A1 |
20060116713 | Sepetka et al. | Jun 2006 | A1 |
20060116750 | Hebert et al. | Jun 2006 | A1 |
20060184238 | Kaufmann et al. | Aug 2006 | A1 |
20060195118 | Richardson | Aug 2006 | A1 |
20060206148 | Khairkhahan et al. | Sep 2006 | A1 |
20060206200 | Garcia et al. | Sep 2006 | A1 |
20060206201 | Garcia et al. | Sep 2006 | A1 |
20060212127 | Karabey et al. | Sep 2006 | A1 |
20060271149 | Berez et al. | Nov 2006 | A1 |
20060271153 | Garcia et al. | Nov 2006 | A1 |
20060276910 | Weber | Dec 2006 | A1 |
20070021816 | Rudin | Jan 2007 | A1 |
20070043419 | Nikolchev et al. | Feb 2007 | A1 |
20070055365 | Greenberg et al. | Mar 2007 | A1 |
20070060994 | Gobran et al. | Mar 2007 | A1 |
20070073379 | Chang | Mar 2007 | A1 |
20070077347 | Richter | Apr 2007 | A1 |
20070100321 | Rudakov et al. | May 2007 | A1 |
20070100414 | Licata | May 2007 | A1 |
20070100430 | Rudakov et al. | May 2007 | A1 |
20070112415 | Bartlett | May 2007 | A1 |
20070119295 | McCullagh | May 2007 | A1 |
20070123969 | Gianotti | May 2007 | A1 |
20070162104 | Frid | Jul 2007 | A1 |
20070167980 | Figulla et al. | Jul 2007 | A1 |
20070198076 | Hebert et al. | Aug 2007 | A1 |
20070203559 | Freudenthal et al. | Aug 2007 | A1 |
20070203563 | Hebert et al. | Aug 2007 | A1 |
20070208367 | Fiorella et al. | Sep 2007 | A1 |
20070208373 | Zaver et al. | Sep 2007 | A1 |
20070208376 | Meng | Sep 2007 | A1 |
20070208415 | Grotheim et al. | Sep 2007 | A1 |
20070219619 | Dieck et al. | Sep 2007 | A1 |
20070225760 | Moszner et al. | Sep 2007 | A1 |
20070233175 | Zaver et al. | Oct 2007 | A1 |
20070239261 | Bose et al. | Oct 2007 | A1 |
20070255386 | Tenne | Nov 2007 | A1 |
20070255388 | Rudakov et al. | Nov 2007 | A1 |
20070280850 | Carlson | Dec 2007 | A1 |
20070299500 | Hebert et al. | Dec 2007 | A1 |
20070299501 | Hebert et al. | Dec 2007 | A1 |
20070299502 | Hebert et al. | Dec 2007 | A1 |
20080015673 | Chuter | Jan 2008 | A1 |
20080033341 | Grad | Feb 2008 | A1 |
20080033526 | Atladottir et al. | Feb 2008 | A1 |
20080039930 | Jones et al. | Feb 2008 | A1 |
20080039933 | Yodfat | Feb 2008 | A1 |
20080071351 | Flanagan et al. | Mar 2008 | A1 |
20080082154 | Tseng et al. | Apr 2008 | A1 |
20080114391 | Dieck et al. | May 2008 | A1 |
20080119943 | Armstrong et al. | May 2008 | A1 |
20080125855 | Henkes et al. | May 2008 | A1 |
20080208320 | Tan-Malecki et al. | Aug 2008 | A1 |
20080221666 | Licata et al. | Sep 2008 | A1 |
20080221670 | Clerc et al. | Sep 2008 | A1 |
20080221671 | Chouinard et al. | Sep 2008 | A1 |
20080255654 | Hebert et al. | Oct 2008 | A1 |
20080255655 | Kusleika et al. | Oct 2008 | A1 |
20080262590 | Murray | Oct 2008 | A1 |
20080269774 | Garcia et al. | Oct 2008 | A1 |
20080275497 | Palmer et al. | Nov 2008 | A1 |
20080275498 | Palmer et al. | Nov 2008 | A1 |
20080294104 | Mawad | Nov 2008 | A1 |
20080300667 | Hebert et al. | Dec 2008 | A1 |
20080300668 | Bonsignore | Dec 2008 | A1 |
20080300673 | Clerc et al. | Dec 2008 | A1 |
20090024202 | Dave et al. | Jan 2009 | A1 |
20090024205 | Hebert et al. | Jan 2009 | A1 |
20090030496 | Kaufmann | Jan 2009 | A1 |
20090030497 | Metcalf et al. | Jan 2009 | A1 |
20090054981 | Frid et al. | Feb 2009 | A1 |
20090099643 | Hyodoh et al. | Apr 2009 | A1 |
20090105802 | Henry et al. | Apr 2009 | A1 |
20090105803 | Shelso | Apr 2009 | A1 |
20090125093 | Hansen | May 2009 | A1 |
20090192536 | Berez et al. | Jul 2009 | A1 |
20090192587 | Frid | Jul 2009 | A1 |
20090198318 | Berez et al. | Aug 2009 | A1 |
20090216307 | Kaufmann et al. | Aug 2009 | A1 |
20090222035 | Schneiderman | Sep 2009 | A1 |
20090270974 | Berez et al. | Oct 2009 | A1 |
20090287241 | Berez et al. | Nov 2009 | A1 |
20090287288 | Berez et al. | Nov 2009 | A1 |
20090288000 | McPherson | Nov 2009 | A1 |
20090292348 | Berez et al. | Nov 2009 | A1 |
20090318947 | Garcia et al. | Dec 2009 | A1 |
20090319017 | Berez et al. | Dec 2009 | A1 |
20100010624 | Berez et al. | Jan 2010 | A1 |
20100042200 | Richter et al. | Feb 2010 | A1 |
20100061604 | Nahm et al. | Mar 2010 | A1 |
20100063531 | Rudakov et al. | Mar 2010 | A1 |
20100070024 | Venturelli et al. | Mar 2010 | A1 |
20100076317 | Babic et al. | Mar 2010 | A1 |
20100152834 | Hannes et al. | Jun 2010 | A1 |
20100161025 | Kuppurathanam et al. | Jun 2010 | A1 |
20100174269 | Tompkins et al. | Jul 2010 | A1 |
20100174309 | Fulkerson et al. | Jul 2010 | A1 |
20100179583 | Carpenter et al. | Jul 2010 | A1 |
20100179647 | Carpenter et al. | Jul 2010 | A1 |
20100198334 | Yodfat et al. | Aug 2010 | A1 |
20100204779 | Schuessler et al. | Aug 2010 | A1 |
20100211154 | Murayama | Aug 2010 | A1 |
20100222864 | Rivelli, Jr. et al. | Sep 2010 | A1 |
20100241214 | Holzer et al. | Sep 2010 | A1 |
20100256732 | Shin et al. | Oct 2010 | A1 |
20100256733 | Schuessler | Oct 2010 | A1 |
20100280587 | Ortiz et al. | Nov 2010 | A1 |
20100318174 | Shaolian et al. | Dec 2010 | A1 |
20100318178 | Rapaport et al. | Dec 2010 | A1 |
20110016427 | Douen | Jan 2011 | A1 |
20110040372 | Hansen et al. | Feb 2011 | A1 |
20110046718 | Cattaneo | Feb 2011 | A1 |
20110046720 | Shalev et al. | Feb 2011 | A1 |
20110054589 | Bashiri et al. | Mar 2011 | A1 |
20110166592 | Garcia et al. | Jul 2011 | A1 |
20110166637 | Irwin et al. | Jul 2011 | A1 |
20110166639 | Pulnev et al. | Jul 2011 | A1 |
20110179389 | Douen | Jul 2011 | A1 |
20110184451 | Sahl | Jul 2011 | A1 |
20110190862 | Bashiri et al. | Aug 2011 | A1 |
20110245862 | Dieck et al. | Oct 2011 | A1 |
20110270178 | Fiorella et al. | Nov 2011 | A1 |
20120035643 | Khairkhahan et al. | Feb 2012 | A1 |
20120041459 | Fiorella et al. | Feb 2012 | A1 |
20120158124 | Zaver et al. | Jun 2012 | A1 |
20120253454 | Costello | Oct 2012 | A1 |
20120290067 | Cam | Nov 2012 | A1 |
20120316638 | Grad et al. | Dec 2012 | A1 |
20120323309 | Cattaneo | Dec 2012 | A1 |
20130116773 | Roeder et al. | May 2013 | A1 |
20130123901 | Connor et al. | May 2013 | A1 |
20130138202 | Paul et al. | May 2013 | A1 |
20130172975 | Berez et al. | Jul 2013 | A1 |
20130190856 | von Oepen et al. | Jul 2013 | A1 |
20130204347 | Armstrong et al. | Aug 2013 | A1 |
20130211489 | Makower et al. | Aug 2013 | A1 |
20130211497 | Charlebois et al. | Aug 2013 | A1 |
20130274849 | Zaver et al. | Oct 2013 | A1 |
20140018843 | Berez et al. | Jan 2014 | A1 |
20140074149 | Garcia et al. | Mar 2014 | A1 |
20140121744 | Kusleika | May 2014 | A1 |
20140121745 | Kusleika | May 2014 | A1 |
20140121746 | Kusleika et al. | May 2014 | A1 |
20140128957 | Losordo et al. | May 2014 | A1 |
20140222130 | Kusleika | Aug 2014 | A1 |
20140316454 | Zaver et al. | Oct 2014 | A1 |
20140336741 | Connor et al. | Nov 2014 | A1 |
20150359646 | Kusleika | Dec 2015 | A1 |
20170000631 | Kusleika | Jan 2017 | A1 |
Number | Date | Country |
---|---|---|
101472537 | Jul 2009 | CN |
855170 | Jul 1998 | EP |
1683541 | Jul 2006 | EP |
1942972 | Jul 2008 | EP |
1872742 | May 2009 | EP |
2 078 512 | Jul 2009 | EP |
2556210 | Apr 1988 | FR |
10-328216 | Dec 1998 | JP |
11-506686 | Jun 1999 | JP |
11-299901 | Nov 1999 | JP |
2001-509412 | Jul 2001 | JP |
2002-253682 | Sep 2002 | JP |
2003-520103 | Jul 2003 | JP |
2004-049585 | Feb 2004 | JP |
2005-074230 | Mar 2005 | JP |
2006-506201 | Feb 2006 | JP |
2008-502378 | Jan 2008 | JP |
2008-541832 | Nov 2008 | JP |
WO-8800813 | Feb 1988 | WO |
WO-95009586 | Apr 1995 | WO |
WO-95032757 | Dec 1995 | WO |
WO-98004211 | Feb 1998 | WO |
WO-9847447 | Oct 1998 | WO |
WO-99002092 | Jan 1999 | WO |
WO-9905977 | Feb 1999 | WO |
WO-99049812 | Dec 1999 | WO |
WO-01005331 | Jan 2001 | WO |
WO-01052771 | Jul 2001 | WO |
WO-02005729 | Jan 2002 | WO |
WO-02047579 | Jun 2002 | WO |
WO-02054988 | Jan 2003 | WO |
WO-03007840 | Jan 2003 | WO |
WO-03043527 | May 2003 | WO |
WO-03049600 | Jun 2003 | WO |
WO-03057079 | Jul 2003 | WO |
WO-03073963 | Sep 2003 | WO |
WO-2004087006 | Nov 2004 | WO |
WO-2005021061 | Mar 2005 | WO |
WO-2005023149 | Dec 2005 | WO |
WO-2006034140 | Mar 2006 | WO |
WO-2006073745 | Jul 2006 | WO |
WO-2006127005 | Nov 2006 | WO |
WO-2007122396 | Nov 2007 | WO |
WO-20081005898 | Jan 2008 | WO |
WO-2007139689 | Sep 2008 | WO |
WO-2007139699 | Sep 2008 | WO |
WO-2008156683 | Dec 2008 | WO |
WO-2005115118 | Jul 2009 | WO |
WO-2009105710 | Aug 2009 | WO |
WO-2010127838 | Nov 2010 | WO |
WO-2011023105 | Mar 2011 | WO |
WO-2011134663 | Nov 2011 | WO |
Entry |
---|
Benndorf, et al. Treatment of a Ruptured Dissecting Vertebral Artery Aneurysm with Double Stent Placement: Case Report AJNR Am J Neuroradiol, Nov.-Dec. 2001, vol. 22, pp. 1844-1848. |
Brilstra, et al., Treatment of Intracranial Aneurysms by Embolization with Coils: A Systematic Review, Stroke, Journal of the American Heart Association, 1999, vol. 30, pp. 470-476. |
Ferguson, Gary, Physical Factors in the Initiation, Growth and Rupture of Human Intracranial Saccular Aneurysms, J. Neurosurg, Dec. 1972, vol. 37, pp. 666-667. |
Geremia, et al., Embolization of Experimentally Created Aneurysms with Intravascular Stent Devices, ANJR American Journal of Neuroradiology, Aug. 1994, vol. 15, pp. 1223-1231. |
Geremia, et al., Occlusion of Experimentally Created Fusiform Aneurysms with Porous Metallic Stents, ANJR Am J Neuroradiol, Apr. 2000, Issue 21, pp. 739-745. |
Lanzino, et al., Efficacy and Current Limitations of Intravascular Stents for Intracranial Internal Carotid, Vertebral, and Basilar Artery Aneurysms, Journal of Neurosurgery, Oct. 1999, vol. 91, Issue 4, pp. 538-546. |
Lieber, et al., Alteration of Hemodynamics in Aneurysm Models by Stenting: Influence of Stent Porosity, Ann of Biomedical Eng., 1997, vol. 25, pp. 460-469, Buffalo, NY. |
Lieber, et al., The Physics of Endoluminal Stenting in the Treatment of Cerebrovascular Aneurysms, Neurological Research, 2002, Vcol 24, Issue Supplement 1, pp. S32-S42. |
Moss, et al., Vascular Occlusion with a Balloon-Expandable Stent Occluder, Radiology, May 1994, vol. 191, Issue 2, pp. 483-486. |
Pereira, Edgard, History of Endovascular Aneurysm Occlusion, Management of Cerebral Aneurysms, 2004, pp. 11-26. |
Qureshi, Adnan, Endovascular Treatment of Cerebrovascular Diseases and Intracranial Neoplasms, The Lancelet, Mar. 2004, vol. 363, pp. 804-81390. |
Steiger, Pathophysiology of Development and Rupture of Cerebral Aneurysms, Acta Nurochirurgica, Mar. 1990, vol. Supplementum 48, Pages in 62 pages. |
Tenaglia, et al., Ultrasound Guide Wire-Directed Stent Deployment, Duke University Medical Center, Department of Medicine, 1993 USA. |
Yu, et al., A Steady Flow Analysis on the Stented and Non-Stented Sidewall Aneurysm Models, Medical Engineering and Physics, Apr. 1999, Issue 21, pp. 133-141. |
U.S. Appl. No. 14/791,876, filed Jul. 6, 2015. |
U.S. Appl. No. 14/714,619, filed May 18, 2015. |
Number | Date | Country | |
---|---|---|---|
20150359646 A1 | Dec 2015 | US |
Number | Date | Country | |
---|---|---|---|
61720154 | Oct 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13826971 | Mar 2013 | US |
Child | 14833768 | US |